Disclosure Of Interests In Other Entities [Text Block]

Xbrane Biopharma - Filing #679209

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Disclosure of interests in other entities [text block]
Disclosure of interests in subsidiaries [text block]
Disclosure of subsidiaries [text block]
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Profit (loss), attributable to non-controlling interests
SEK
SEK
Non-controlling interests
SEK
SEK
Current assets
461 693 SEK
513 524 SEK
Non-current assets
191 815 SEK
176 990 SEK
Current liabilities
326 557 SEK
236 569 SEK
Non-current liabilities
155 616 SEK
29 058 SEK
Revenue
238 729 SEK
57 618 SEK
Profit (loss)
388 172 SEK
388 172 SEK
172 513 SEK
172 513 SEK
Comprehensive income
0 SEK
0 SEK
388 373 SEK
388 172 SEK
201,000 SEK
SEK
167 356 SEK
172 513 SEK
5 157 SEK
SEK
Disclosure of interests in associates [text block]
Disclosure of associates [text block]
Disclosure of associates [abstract]
Disclosure of associates [line items]
Profit (loss) from continuing operations
322 028 SEK
168 513 SEK
Profit (loss) from discontinued operations
66 144 SEK
4 001 SEK
Other comprehensive income
201,000 SEK
201,000 SEK
5 157 SEK
5 157 SEK
Disclosure of interests in joint arrangements [text block]
Disclosure of joint ventures [text block]
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents
65 402 SEK
193 994 SEK
295 180 SEK
Tax expense (income)
SEK
SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.